EMA approves addition of sites to Greenwich LifeSciences’ breast cancer trial
The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...
Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
Based on the interest of principal investigators at additional sites, the Company plans to submit applications to EMA regulators to add 5-10 additional sites in Ireland, Romania, and potentially other ...
Greenwich LifeSciences expands FLAMINGO-01 clinical trial into Europe
Greenwich LifeSciences (GLSI), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is ...
Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland
STAFFORD, Texas, Jan. 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical ...
news.stocktradersdaily4d
How to Take Advantage of moves in (GLSI)
Check the time stamp on this data. Updated AI-Generated Signals for Greenwich Lifesciences Inc. (GLSI) available here: GLSI.